201
|
Schneider A, Seck K, Hahn E, Schmalzried H, Kiechle M, Schmalfeldt B. Borderlinetumor und Fertilitätserhalt: eine retrospektive Analyse anhand eigener Daten hinsichtlich Schwangerschaftsrate, Auftreten eines Rezidivs und Überleben. Geburtshilfe Frauenheilkd 2013. [DOI: 10.1055/s-0033-1347871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
202
|
Ettl J, Grosse Lackmann K, Hapfelmeier A, Klein E, Paepke S, Petry C, Specht K, Hoefler H, Kiechle M. Prospective comparison of uPA/PAI-1 and EndoPredict-clin score in ER-positive, HER2-negative breast cancer: Impact on risk stratification and treatment decisions. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
581 Background: Adjuvant therapy decisions in breast cancer patients are based on accurate risk assessment. UPA/PAI-1 can be used for risk evaluation. Recently, the EndoPredict-clin score (EPclin), a second generation multigene test has been introduced into clinical practice. Aim of this prospective study is to compare risk assessment by uPA/PAI-1 and EPclin and to determine, how these parameters influence treatment decisions. Methods: 100 consecutive cases of ER-pos, HER2neg, intermediate risk breast cancer cases were enrolled in this study. EPclin and uPA/PAI-1 (for G2-tumors) were obtained by central pathology assessment of the patients´ surgical specimen. Type of adjuvant treatment was chosen after case discussion in an interdisciplinary tumor conference. Results: 94 Patients (pt) have been evaluated. Tumor grading within the presented cohort was as follows: G1: 15 pt (16%), G2: 66 pt (70%), G3: 13 pt (14%). 20 pt (21%) had positive axillary lymph node involvement. Tumor size was less than 1 cm in 27 pt (29%). EPclin could be assessed in 94 pt (100%). 32 pt (34%) were classified as “high risk” whereas 62 pt (66%) were classified as “low risk”. uPA/PAI was obtained from 54 pt (57%). 36 pt (67%) out of these 54 pt had high uPA/PAI-1 levels whereas 18 pt (33%) showed low uPA/PAI-1 levels. Only 2 pt (4%) with low uPA/PAI-1 levels were classified as “high risk” with EPclin, whereas 17 pt (32%) with high uPA/PAI-1 were classified as “low risk” via EPclin (p=0,003). In 29 cases (31%) treatment decision was influenced by EPclin: In 26 pt (28%) adjuvant chemotherapy (ctx) was omitted whereas in 3 pt (3%) ctx was added following the EPclin. Conclusions: This prospective study shows for the first time, that high risk status according to the EPclin score is strongly associated with a high risk status as defined by uPA/PAI-1. Providing analytically valid results for all patients evaluated EPclin’s clinical practicability was clearly superior to uPA/PAI-1. This finding, combined with the fact that EPclin assigns twice as many patients to the low risk group indicated that EPclin is a more versatile and powerful tool to help spare patients from chemotherapy than uPA/PAI-1.
Collapse
Affiliation(s)
- Johannes Ettl
- Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Kirsten Grosse Lackmann
- Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Alexander Hapfelmeier
- Institute of Medical Statistics and Epidemiology, Klinikum rechts der Isar, Technische Universität München, München, Germany
| | - Evelyn Klein
- Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Stefan Paepke
- Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | | | - Katja Specht
- Insitute of Pathology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Heinz Hoefler
- Intitute of Pathology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Marion Kiechle
- Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| |
Collapse
|
203
|
Wiedemann F, Buessing A, Halle M, Kiechle M, Kohls N, Ostermann T, Sattler D, Ettl J. Iyengar yoga compared to exercise in women with stage I-III breast cancer: Feasibility of therapeutic interventions during adjuvant cytotoxic or endocrine therapy. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.e20623] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20623 Background: Exercise and mind/body intervention studies have shown benefits when undertaken during cancer treatment. This ongoing trial aims to elucidate the different effects of yoga and conventional exercise on physical and psychological factors in breast cancer patients undergoing endocrine or cytotoxic therapy. This first interim analysis presents feasibility data comparing the two mentioned interventions. Methods: Patients are randomly assigned to receive Iyengar-yoga or conventional exercise on a 1:1 ratio during adjuvant therapy. The intervention consists of a weekly 60-minute yoga or physiotherapy exercise session together with individual home-based, self-contained 20-minute sessions twice a week. Data assessments via questionnaires are done at baseline, right after the 12-week intervention period and 2 months after the end of intervention. Patient accrual within two breast care units started in April 2011 with 66 patients being on study to date (2013, Jan 25). Results: So far, 57 patients (yoga: n=28; exercise: n=29) have completed the trial, while 9 patients dropped out (yoga: 5 patients; exercise: 4 patients). 46 patients received cytotoxic therapy (mean age: 48 y) and 11 patients received endocrine therapy (mean age: 60 y). 8 women participating either in yoga or exercise intervention were younger than 35 years (14%) and 6 women were older than 65 years (11%). Mean number of attended sessions is 9.0 (yoga: 9.3; exercise: 8.8; age >65: 10.3). Overall 19 patients (33%) attended 11-12 out of 12 sessions (yoga: 32%; exercise: 35%; age >65: 67%), 20 patients (35%) attended 8-10 sessions (yoga: 54%; exercise: 17%; age >65: 17%), while 18 women (32%) participated only in 5-7 sessions (yoga: 14%; exercise: 48%; age >65: 17%). 10 out of 51 participants accomplished 40 minutes of home-based training per week (yoga: 11%; exercise: 29%; age >65: 50%). Conclusions: Yoga and exercise interventions are feasible during cancer treatment, although amount and frequency of training should be accommodated to individual condition. Both interventions seem to be practicable for elderly (> 65 years) patients and for patients undergoing cytotoxic therapy.
Collapse
Affiliation(s)
- Florian Wiedemann
- Quality of Life, Spirituality and Coping, Universität Witten/Herdecke, Herdecke, Germany
| | - Arndt Buessing
- Quality of Life, Spirituality and Coping, Universität Witten/Herdecke, Herdecke, Germany
| | - Martin Halle
- Zentrum für Prävention und Sportmedizin, Technische Universität München, Munich, Germany
| | - Marion Kiechle
- Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Nikola Kohls
- Generation Research Program, Ludwig-Maximilians-Universität München, Bad Tölz, Germany
| | - Thomas Ostermann
- Quality of Life, Spirituality and Coping, Universität Witten/Herdecke, Herdecke, Germany
| | | | - Johannes Ettl
- Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| |
Collapse
|
204
|
Paepke S, Kiechle M. Selective tissue adhesion reducing seroma formation in extensive breast surgery: the application of TissuGlu® - only problematic case solver or possible standard procedure? Eur J Surg Oncol 2013. [DOI: 10.1016/j.ejso.2013.01.161] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
205
|
Lehner A, Magdolen V, Schuster T, Kotzsch M, Kiechle M, Meindl A, Sweep FCGJ, Span PN, Gross E. Downregulation of serine protease HTRA1 is associated with poor survival in breast cancer. PLoS One 2013; 8:e60359. [PMID: 23580433 PMCID: PMC3620283 DOI: 10.1371/journal.pone.0060359] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2012] [Accepted: 02/26/2013] [Indexed: 11/24/2022] Open
Abstract
HTRA1 is a highly conserved serine protease which has been implicated in suppression of epithelial-to-mesenchymal-transition (EMT) and cell motility in breast cancer. Its prognostic relevance for breast cancer is unclear so far. Therefore, we evaluated the impact of HTRA1 mRNA expression on patient outcome using a cohort of 131 breast cancer patients as well as a validation cohort including 2809 publically available data sets. Additionally, we aimed at investigating for the presence of promoter hypermethylation as a mechanism for silencing the HTRA1 gene in breast tumors. HTRA1 downregulation was detected in more than 50% of the breast cancer specimens and was associated with higher tumor stage (p = 0.025). By applying Cox proportional hazard models, we observed favorable overall (OS) and disease-free survival (DFS) related to high HTRA1 expression (HR = 0.45 [CI 0.23-0.90], p = 0.023; HR = 0.55 [CI 0.32-0.94], p = 0.028, respectively), with even more pronounced impact in node-positive patients (HR = 0.21 [CI 0.07-0.63], p = 0.006; HR = 0.29 [CI 0.13-0.65], p = 0.002, respectively). Moreover, HTRA1 remained a statistically significant factor predicting DFS among established clinical parameters in the multivariable analysis. Its impact on patient outcome was independently confirmed in the validation set (for relapse-free survival (n = 2809): HR = 0.79 [CI 0.7-0.9], log-rank p = 0.0003; for OS (n = 971): HR = 0.63 [CI 0.48-0.83], log-rank p = 0.0009). In promoter analyses, we in fact detected methylation of HTRA1 in a small subset of breast cancer specimens (two out of a series of 12), and in MCF-7 breast cancer cells which exhibited 22-fold lower HTRA1 mRNA expression levels compared to unmethylated MDA-MB-231 cells. In conclusion, we show that downregulation of HTRA1 is associated with shorter patient survival, particularly in node-positive breast cancer. Since HTRA1 loss was demonstrated to induce EMT and cancer cell invasion, these patients might benefit from demethylating agents or histone deacetylase inhibitors previously reported to lead to HTRA1 upregulation, or from novel small-molecule inhibitors targeting EMT-related processes.
Collapse
Affiliation(s)
- Anna Lehner
- Department of Gynecology and Obstetrics, Technische Universität München, Munich, Germany
| | - Viktor Magdolen
- Department of Gynecology and Obstetrics, Technische Universität München, Munich, Germany
| | - Tibor Schuster
- Institute of Medical Statistics and Epidemiology, Technische Universität München, Munich, Germany
| | - Matthias Kotzsch
- Institute of Pathology, Dresden University of Technology, Dresden, Germany
| | - Marion Kiechle
- Department of Gynecology and Obstetrics, Technische Universität München, Munich, Germany
| | - Alfons Meindl
- Department of Gynecology and Obstetrics, Technische Universität München, Munich, Germany
| | - Fred C. G. J. Sweep
- Department of Laboratory Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
| | - Paul N. Span
- Department of Radiation Oncology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
| | - Eva Gross
- Department of Gynecology and Obstetrics, Technische Universität München, Munich, Germany
| |
Collapse
|
206
|
Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CGJ, Lisboa BW, Lux MP, Beck T, Hasmüller S, Kiechle M, Jänicke F, Thomssen C. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer 2013; 49:1825-35. [PMID: 23490655 DOI: 10.1016/j.ejca.2013.01.007] [Citation(s) in RCA: 122] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2012] [Revised: 01/03/2013] [Accepted: 01/09/2013] [Indexed: 11/25/2022]
Abstract
AIM Final 10-year analysis of the prospective randomised Chemo-N0 trial is presented. Based on the Chemo-N0 interim results and an European Organisation for Research and Treatment of Cancer (EORTC) pooled analysis (n=8377), American Society of Clinical Oncology (ASCO) and Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) guidelines recommend invasion and metastasis markers urokinase-type plasminogen activator (uPA)/plasminogen activator inhibitor-1 (PAI-1) for risk assessment and treatment decision in node-negative (N0) breast cancer (BC). METHODS The final Chemo-N0 trial analysis (recruitment 1993-1998; n=647; 12 centres) comprises 113 (5-167) months of median follow-up. Patients with low-uPA and PAI-1 tumour tissue levels (n=283) were observed. External quality assurance guaranteed uPA/PAI-1 enzyme-linked immunosorbent assay (ELISA) standardisation. Of 364 high uPA and/or PAI-1 patients, 242 agreed to randomisation for CMF chemotherapy (n=117) versus observation (n=125). RESULTS Actuarial 10-year recurrence rate (without any adjuvant systemic therapy) for high-uPA/PAI-1 observation group patients (randomised and non-randomised) was 23.0%, in contrast to only 12.9% for low-uPA/PAI-1 patients (plog-rank=0.011). High-risk patients randomised to cyclophosphamide-methotrexate-5-fluorouracil (CMF) therapy had a 26.0% lower estimated probability of disease recurrence than those randomised for observation (intention-to-treat (ITT)-analysis: hazard ratio (HR) 0.74 (0.44-1.27); plog-rank=0.28). Per-protocol analysis demonstrated significant treatment benefit: HR 0.48 (0.26-0.88), p=0.019, disease-free survival (DFS) Cox regression, adjusted for tumour stage and grade. CONCLUSIONS Chemo-N0 is the first prospective biomarker-based therapy trial in early BC defining patients reaching good long-term DFS without adjuvant systemic therapy. Using a standardised uPA/PAI-1 ELISA, almost half of N0-patients could be spared chemotherapy, while high-risk patients benefit from adjuvant chemotherapy. These 10-year results validate the long-term prognostic impact of uPA/PAI-1 and the benefit from adjuvant chemotherapy in the high-uPA/PAI-1 group at highest level of evidence. They thus support the guideline-based routine use of uPA/PAI-1 for risk-adapted individualised therapy decisions in N0 breast cancer.
Collapse
Affiliation(s)
- N Harbeck
- Brustzentrum, Frauenklinik Maistrasse, Universitaet München, 80337 Munich, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
207
|
Andergassen U, Kasprowicz NS, Hepp P, Schindlbeck C, Harbeck N, Kiechle M, Sommer H, Beckmann MW, Friese K, Janni W, Rack B, Scholz C. Participation in the SUCCESS-A Trial Improves Intensity and Quality of Care for Patients with Primary Breast Cancer. Geburtshilfe Frauenheilkd 2013; 73:63-69. [PMID: 24771886 DOI: 10.1055/s-0032-1328147] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2012] [Revised: 12/13/2012] [Accepted: 12/13/2012] [Indexed: 12/21/2022] Open
Abstract
The SUCCESS-A trial is a prospective, multicenter, phase III clinical trial for high-risk primary breast cancer. It compares disease-free survival after randomization in patients treated with fluorouracil, epirubicin and cyclophosphamide followed by 3 cycles of docetaxel (FEC-D) with that of patients treated with 3 cycles of FEC followed by 3 cycles of gemcitabine and docetaxel (FEC-DG). After a second randomization patients were treated with zoledronate for 2 or 5 years. A total of 251 centers took part in the trial and 3754 patients were recruited over a period of 18 months which ended in March 2007. In a questionnaire-based survey we investigated the impact of enrollment in the trial on patient care, the choice of chemotherapy protocol and access to current oncologic information as well as overall satisfaction in the respective centers. Analysis of the 78 questionnaires returned showed that 40 % of the centers had never previously enrolled patients with these indications in clinical studies. Prior to participating in the study, 4 % of the centers prescribed CMF or other protocols in patients with high-primary breast cancer risk, 46 % administered anthracycline-based chemotherapy and 50 % gave taxane-based chemotherapy. Around half of the participating centers noted that intensity of care and overall quality of care became even better and that access to breast cancer-specific information improved through participation in the trial. After their experience with the SUCCESS-A trial, all of the centers stated that they were prepared to enroll patients in clinical phase III trials again in the future. These data indicate that both patients and physicians benefit from clinical trials, as enrollment improves treatment strategies and individual patient care, irrespective of study endpoints.
Collapse
Affiliation(s)
- U Andergassen
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Ludwig-Maximilians-Universität, München
| | - N S Kasprowicz
- Frauenklinik, Klinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf
| | - P Hepp
- Frauenklinik, Klinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf
| | | | - N Harbeck
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Ludwig-Maximilians-Universität, München ; Brustzentrum der Universität, Klinikum der Ludwig-Maximilians-Universität, München
| | - M Kiechle
- Frauenklinik, Klinikum rechts der Isar der TU München, München
| | - H Sommer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Ludwig-Maximilians-Universität, München
| | | | - K Friese
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Ludwig-Maximilians-Universität, München
| | - W Janni
- Frauenklinik, Klinikum der Universität Ulm, Ulm
| | - B Rack
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Ludwig-Maximilians-Universität, München
| | - C Scholz
- Frauenklinik, Klinikum der Universität Ulm, Ulm
| | | |
Collapse
|
208
|
Volkmann J, Reuning U, Rudelius M, Häfner N, Schuster T, Becker V Ros A, Weimer J, Hilpert F, Kiechle M, Dürst M, Arnold N, Schmalfeldt B, Meindl A, Ramser J. High expression of crystallin αB represents an independent molecular marker for unfavourable ovarian cancer patient outcome and impairs TRAIL- and cisplatin-induced apoptosis in human ovarian cancer cells. Int J Cancer 2012; 132:2820-32. [PMID: 23225306 DOI: 10.1002/ijc.27975] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2012] [Accepted: 11/19/2012] [Indexed: 01/27/2023]
Abstract
Dysregulated apoptotic pathways are regarded as major reasons for chemoresistance development as a particular challenge in ovarian cancer therapy. In search of molecular factors affecting human ovarian cancer cell apoptosis and, consequently, patient survival, we examined tumors of 103 platinum-/taxane-treated ovarian cancer patients by mRNA-array hybridization, qPCR, and immunohistochemistry. We identified high expression of crystallin αB (CRYAB), a proposed negative regulator of tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-mediated apoptosis. By Kaplan Meier analysis, this factor turned out to be significantly associated with poor patient outcome [overall survival (OS) p = 0.001, recurrence-free survival (RFS) p = 0.003]. Elevated hazard ratios (HR) were estimated with regard to OS (HR = 2.11, 95% CI 1.10-4.06) and RFS (HR = 1.92, 95% CI 1.07-3.47) in multivariable analyses. These associations were confirmed in independent, publicly available mRNA data comprising 431 patients for OS (p < 0.001) and 413 for RFS (p < 0.001). Our findings were validated by studying apoptotic events in cultured human ovarian cancer cells which were stably transfected to express elevated CRYAB levels. These data emphasized the crucial role of CRYAB in human ovarian cancer biology since TRAIL- as well as cisplatin-induced apoptosis was significantly impaired as a function of enhanced CRYAB expression. Taken together, we identified CRYAB as an independent biomarker for unfavourable outcome of human ovarian cancer patients. Since TRAIL is currently tested as anti-cancer drug and large proportions of the present patient cohort displayed low CRYAB levels in their tumors, CRYAB may enable the selection of patient subgroups benefiting most from TRAIL-containing therapy.
Collapse
Affiliation(s)
- Juliane Volkmann
- Clinic of Gynecology and Obstetrics, Klinikum rechts der Isar, Technische Universitaet Muenchen, Munich, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
209
|
Jacobs VR, Augustin D, Wischnik A, Kiechle M, Hoess C, Steinkohl O, Rack B, Kapitza T, Krase P. Abstract P5-15-04: CTX and CTX-related direct medication costs saved by testing biomarkers uPA and PAI-1 in primary breast cancer: Results of a prospective multi-center study at Certified Breast Centers in Germany. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p5-15-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Biomarkers uPA and PAI-1 are guideline recommended by ASCO, USA, and AGO, Germany, to be used in primary breast cancer to avoid unnecessary CTX in medium risk recurrence patients [G2, N−, HR+, HER2neu−, >35 years]. This study was performed to verify in normal clinical settings how many CTX cycles and how much CTX-related direct medication costs can be avoided by uPA/PAI-1 testing.
Methods: Prospective, non-interventional, multi-center study over two years among six Certified Breast Centers in Germany to analyze application of uPA/PAI-1 and consecutive decision making in the clinical setting for AOK Bayern-insured patients. CTX regimen and cycles avoided were identified for each case and direct costs for CTX and CTX-related medication costs for concomitant medication calculated for each patient individually according to body weight and body surface as well as potential FN prophylaxis according to physicians' decision. All medication costs were taken from the pharmaceutical price list for Germany Rote Liste of 2012. EURO [€] to US Dollar conversion rate as of June 12 2012: € 1.00 = US$ 1.25.
Results: In n=93 breast cancers n=35 CTX (37.6%; FEC n=25, FEC+DOC n=8 and TC n=2) were avoided according to uPA/PAI-1 test result. Consecutively 210 CTX cycles or 12.1 years of CTX application were saved improving patients' quality of life. uPA/PAI-1 testing saved direct medication costs for avoided CTX of US$ 221.816, CTX-related concomitant medication of US$ 34.353 and G-CSF prophylaxis of US$ 25.749, overall US$ 281.918. At process costs for a single uPA/PAI-1 test calculated at US$ 359, uPA/PAI-1 testing resulted in additional costs of US$ 33.387 for all breast cancer cases. Overall, testing of uPA/PAI-1 has been proven to be cost-effective regarding direct medication costs alone at a return-on-investment ratio of 8.4:1. Indirect cost savings further increase this ROI.
Conclusions: Innovative and individual cancer diagnostics like biomarkers uPA/PAI-1 can decrease need of CTX and increase patients' quality of life and thereby reduce costs for health care systems. Since application of this test is inadequate at present time measures are suggested to fully implement such cost-effective diagnostics.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-15-04.
Collapse
Affiliation(s)
- VR Jacobs
- Paracelsus Medical University, Salzburg, Austria; Klinikum Deggendorf, Deggendorf, Germany; Klinikum Augsburg, Augsburg, Germany; Technical University Munich (TUM), Germany; Cooperative Breast Center Ebersberg-Rosenheim. Kreisklinikum Ebersberg, Ebersberg, Germany; Klinikum Dritter Orden, Munich, Germany; Ludwig-Maximilian-University (LMU), Munich, Germany; Top Expertise, Germering/Munich, Germany; AOK Bayern, Munich, Germany
| | - D Augustin
- Paracelsus Medical University, Salzburg, Austria; Klinikum Deggendorf, Deggendorf, Germany; Klinikum Augsburg, Augsburg, Germany; Technical University Munich (TUM), Germany; Cooperative Breast Center Ebersberg-Rosenheim. Kreisklinikum Ebersberg, Ebersberg, Germany; Klinikum Dritter Orden, Munich, Germany; Ludwig-Maximilian-University (LMU), Munich, Germany; Top Expertise, Germering/Munich, Germany; AOK Bayern, Munich, Germany
| | - A Wischnik
- Paracelsus Medical University, Salzburg, Austria; Klinikum Deggendorf, Deggendorf, Germany; Klinikum Augsburg, Augsburg, Germany; Technical University Munich (TUM), Germany; Cooperative Breast Center Ebersberg-Rosenheim. Kreisklinikum Ebersberg, Ebersberg, Germany; Klinikum Dritter Orden, Munich, Germany; Ludwig-Maximilian-University (LMU), Munich, Germany; Top Expertise, Germering/Munich, Germany; AOK Bayern, Munich, Germany
| | - M Kiechle
- Paracelsus Medical University, Salzburg, Austria; Klinikum Deggendorf, Deggendorf, Germany; Klinikum Augsburg, Augsburg, Germany; Technical University Munich (TUM), Germany; Cooperative Breast Center Ebersberg-Rosenheim. Kreisklinikum Ebersberg, Ebersberg, Germany; Klinikum Dritter Orden, Munich, Germany; Ludwig-Maximilian-University (LMU), Munich, Germany; Top Expertise, Germering/Munich, Germany; AOK Bayern, Munich, Germany
| | - C Hoess
- Paracelsus Medical University, Salzburg, Austria; Klinikum Deggendorf, Deggendorf, Germany; Klinikum Augsburg, Augsburg, Germany; Technical University Munich (TUM), Germany; Cooperative Breast Center Ebersberg-Rosenheim. Kreisklinikum Ebersberg, Ebersberg, Germany; Klinikum Dritter Orden, Munich, Germany; Ludwig-Maximilian-University (LMU), Munich, Germany; Top Expertise, Germering/Munich, Germany; AOK Bayern, Munich, Germany
| | - O Steinkohl
- Paracelsus Medical University, Salzburg, Austria; Klinikum Deggendorf, Deggendorf, Germany; Klinikum Augsburg, Augsburg, Germany; Technical University Munich (TUM), Germany; Cooperative Breast Center Ebersberg-Rosenheim. Kreisklinikum Ebersberg, Ebersberg, Germany; Klinikum Dritter Orden, Munich, Germany; Ludwig-Maximilian-University (LMU), Munich, Germany; Top Expertise, Germering/Munich, Germany; AOK Bayern, Munich, Germany
| | - B Rack
- Paracelsus Medical University, Salzburg, Austria; Klinikum Deggendorf, Deggendorf, Germany; Klinikum Augsburg, Augsburg, Germany; Technical University Munich (TUM), Germany; Cooperative Breast Center Ebersberg-Rosenheim. Kreisklinikum Ebersberg, Ebersberg, Germany; Klinikum Dritter Orden, Munich, Germany; Ludwig-Maximilian-University (LMU), Munich, Germany; Top Expertise, Germering/Munich, Germany; AOK Bayern, Munich, Germany
| | - T Kapitza
- Paracelsus Medical University, Salzburg, Austria; Klinikum Deggendorf, Deggendorf, Germany; Klinikum Augsburg, Augsburg, Germany; Technical University Munich (TUM), Germany; Cooperative Breast Center Ebersberg-Rosenheim. Kreisklinikum Ebersberg, Ebersberg, Germany; Klinikum Dritter Orden, Munich, Germany; Ludwig-Maximilian-University (LMU), Munich, Germany; Top Expertise, Germering/Munich, Germany; AOK Bayern, Munich, Germany
| | - P Krase
- Paracelsus Medical University, Salzburg, Austria; Klinikum Deggendorf, Deggendorf, Germany; Klinikum Augsburg, Augsburg, Germany; Technical University Munich (TUM), Germany; Cooperative Breast Center Ebersberg-Rosenheim. Kreisklinikum Ebersberg, Ebersberg, Germany; Klinikum Dritter Orden, Munich, Germany; Ludwig-Maximilian-University (LMU), Munich, Germany; Top Expertise, Germering/Munich, Germany; AOK Bayern, Munich, Germany
| |
Collapse
|
210
|
Rhiem K, Engel C, Graeser M, Zachariae S, Kast K, Kiechle M, Ditsch N, Janni W, Mundhenke C, Golatta M, Varga D, Preisler-Adams S, Heinrich T, Bick U, Gadzicki D, Briest S, Meindl A, Schmutzler RK. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res 2012; 14:R156. [PMID: 23216834 PMCID: PMC4053142 DOI: 10.1186/bcr3369] [Citation(s) in RCA: 77] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2012] [Accepted: 10/23/2012] [Indexed: 01/23/2023] Open
Abstract
Introduction While it has been reported that the risk of contralateral breast cancer in patients from BRCA1 or BRCA2 positive families is elevated, little is known about contralateral breast cancer risk in patients from high risk families that tested negative for BRCA1/2 mutations. Methods A retrospective, multicenter cohort study was performed from 1996 to 2011 and comprised 6,235 women with unilateral breast cancer from 6,230 high risk families that had tested positive for BRCA1 (n = 1,154) or BRCA2 (n = 575) mutations or tested negative (n = 4,501). Cumulative contralateral breast cancer risks were calculated using the Kaplan-Meier product-limit method and were compared between groups using the log-rank test. Cox regression analysis was applied to assess the impact of the age at first breast cancer and the familial history stratified by mutation status. Results The cumulative risk of contralateral breast cancer 25 years after first breast cancer was 44.1% (95%CI, 37.6% to 50.6%) for patients from BRCA1 positive families, 33.5% (95%CI, 22.4% to 44.7%) for patients from BRCA2 positive families and 17.2% (95%CI, 14.5% to 19.9%) for patients from families that tested negative for BRCA1/2 mutations. Younger age at first breast cancer was associated with a higher risk of contralateral breast cancer. For women who had their first breast cancer before the age of 40 years, the cumulative risk of contralateral breast cancer after 25 years was 55.1% for BRCA1, 38.4% for BRCA2, and 28.4% for patients from BRCA1/2 negative families. If the first breast cancer was diagnosed at the age of 50 or later, 25-year cumulative risks were 21.6% for BRCA1, 15.5% for BRCA2, and 12.9% for BRCA1/2 negative families. Conclusions Contralateral breast cancer risk in patients from high risk families that tested negative for BRCA1/2 mutations is similar to the risk in patients with sporadic breast cancer. Thus, the mutation status should guide decision making for contralateral mastectomy.
Collapse
|
211
|
Paepke S, Krol J, Ettl J, Niemeyer M, Kiechle M. Azelluläre Dermis humaner Herkunft (Epiflex®) in der Primär- und Sekundärrekonstruktion – Einzelfallerfahrungen. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1329445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
212
|
Paepke S, Klein E, Ettl J, Niemeyer M, Kiechle M. Nippel-sparende subkutane Mastektomie als dual-plane Rekonstruktion mit fasciocutaner- und Titannetzbedeckung bei Patientinnen mit Makromastie. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1329443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
213
|
Paepke S, Klein E, Kiechle M. Subpectorale Implantateinlage in der onkoplastisch-rekonstruktiven Mammachirurgie – Gewohnheit oder Notwendigkeit? Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1329446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
214
|
Paepke S, Klein E, Paepke D, Niemeyer M, Kiechle M, Ettl J, Krol J. Einsatz porciner azellulärer Dermis (Strattice TM) als gewebeersetzendes und -unterstützendes Interponat zur Implantatabdeckung bei problematischen Weichteilverhältnissen in der plastisch-rekonstruktiven Mammachirurgie. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1329444] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
215
|
Rhiem K, Pfeifer K, Schmutzler RK, Kiechle M. Risk-reducing Surgery in Women at Risk for Familial Breast or Ovarian Cancer. Geburtshilfe Frauenheilkd 2012; 72:833-839. [PMID: 26640291 DOI: 10.1055/s-0032-1315362] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Abstract
An estimated 5 % of breast cancers and 10 % of ovarian cancers may be due to inherited autosomal dominant breast and ovarian cancer alleles BRCA1 und BRCA2. According to population-based studies 1 or 2 women per 1000 carry such a risk allele. The cumulative cancer risk for healthy women with a BRCA-mutation is between 60 and 85 % for breast cancer and between 20 and 60 % for ovarian cancer. Recent studies have reported an increased risk for contralateral breast cancer in women after unilateral breast cancer. Since 1997 the German Cancer Aid has supported an interdisciplinary approach for high-risk women consisting of genetic testing, counselling and prevention in 12 specialised centres. Since 2005 this concept has received additional support from health insurance companies, and results have been assessed with regard to outcomes (e.g. reduced mortality due to more intensive early diagnosis). The number of centres has increased to 15 at various university hospitals. These interdisciplinary centres offer women the opportunity to participate in a structured screening programme for the early diagnosis of breast cancer and provide non-directive counselling on the options for risk-reducing surgery, e.g., prophylactic bilateral salpingo-oophorectomy, prophylactic bilateral mastectomy or contralateral prophylactic mastectomy after unilateral breast cancer. Such surgical interventions can significantly reduce the risk of disease, the respective disease-specific mortality and - particularly prophylactic bilateral salpingo-oophorectomy - total mortality in BRCA-mutation carriers.
Collapse
Affiliation(s)
- K Rhiem
- University Hospital, Center for Familial Breast and Ovarian Cancer, Cologne, Germany
| | - K Pfeifer
- Frauenklinik Rechts der Isar, Technische Universität München, Munich, Germany
| | - R K Schmutzler
- University Hospital, Center for Familial Breast and Ovarian Cancer, Cologne, Germany
| | - M Kiechle
- Frauenklinik Rechts der Isar, Technische Universität München, Munich, Germany
| |
Collapse
|
216
|
Paepke S, Klein E, Ettl J, Niemeyer M, Bronger H, Paepke D, Kiechle M. Nipple-sparing subcutaneous mastectomy (NSSM) as dual-plane prosthetic reconstruction using the modified Wise pattern mastectomy, fasciocutaneous flap, and titan-polypropylen-mesh-interponation in women with macromastia. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.27_suppl.156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
156 Background: Ablative surgery of voluminous, ptotic breasts poses the problem of implant cover of the lower and lateral two thirds that are not coverd by the liftet pectoral muscle. Based on reduction mammaplasty techniques we applied a method that utilizes the excess mammary skin in terms of vertical, lateral, and medial de-epithelialized fascio-cutaneous tissue columns that serve together with a mesh (TiLoop bra) as cover for the subpectoral implant. Methods: Between 06/2009 and 01/2012 we performed 16 nipple and skin sparing mastectomies with marked tissue reduction (defined as difference in weight between implant and resected tissue of more than 300 g) in 7 patients. Indications comprise primary and secondary prophylactic as well as 4 nipple sparing mastectomies after neoadjuvant chemotherapy. Results: Mastectomy weights ranged between 325 and 1100 g; implant volumes ranged between 295 and 800 cm3. There occured five partial necrosis of the nipple-areolar complex (NAC) and three partial skin necrosis at the margin of the vertical incision. Two patients had to be operated on a second time for cosmetic reasons. The overall complication rate was low. Conclusions: The method described herein using the de-epithelialized excess mammary skin and the advantages of the titanized polypropylene mesh archieves stable reconstructions and a safe vascularization of the NAC.
Collapse
Affiliation(s)
- Stefan Paepke
- Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany
| | - Evelyn Klein
- Frauenklinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Johannes Ettl
- Department of Obstetrics and Gynecology, Technical University Munich, Munich, Germany
| | - Markus Niemeyer
- Department of Gynecology and Obstetrics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Holger Bronger
- Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany
| | - Daniela Paepke
- Department of Gynecology, Technical University, Muenchen, Germany
| | - Marion Kiechle
- Department of Obstetrics and Gynecology, Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany
| |
Collapse
|
217
|
Paepke S, Dittmer S, Rezai A, Klein E, Kiechle M. Subpectoral implants in oncoplastic-reconstructive breast surgery: Habit or necessity? J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.27_suppl.161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
161 Background: We perform nipple-sparing subcutaneous mastectomies since 2002. Herein we report on 352 cases, in 156 of which acellular dermis (ADM) or meshs (tetanized polypropylene-mesh) as tissue interponates were used. The standard procedure of subpectoral implant positioning with or without caudo-lateral tissue interponates (acellular dermis or mesh) can lead to postoperative problems due to detachment of muscle. Against this background we did not form a submuscular pocket in individual cases, but instead placed the implant in a cranially and caudally covering ADM or mesh pocket. Methods: Between 06/11 and 03/12 17 patients were operated according to the above protocol, and the short-term follow up analyzed. Patients that had to get radiation therapy were not admitted to the study. Furthermore, we only included patients that were planned to get a second, contralateral operation so that corrections of the first operation were possible. Patients were between 34 and 58 years old. One patient had to receive radiotherapy due to a nodal involvement not diagnosed before. Results: Four patients had received prior surgery. Indications for subcutaneous mastectomies comprised invasive carcinomas with large DCIS, R1 resections or secondary prophylaxis. Mastectomy weights ranged between 225 and 1100 g; implant volumes ranged between 225 and 800 cm3. The cosmetic outcome was excellent, the margins of the implants were not visible. In three cases there was a partial necrosis of the nipple and in two cases a partial skin necrosis with the necessity of a wound revision. Conclusions: Using a ADM- or mesh-pocket instead of subpectoral positioning of the implant makes the operation in individual cases easier. Post-operative mobility is immediate and unrestricted. Since the implant size has to be chosen according to the tissue weight removed, a bilaterally identical cosmetic result can be archieved. Complications inculde a mild seroma formation without the necessity to puncture. However, the small number of cases and the short term follow up do not allow to make any statements about consecutive capsular fibrosis.
Collapse
Affiliation(s)
- Stefan Paepke
- Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany
| | - Sissi Dittmer
- Department of Gynecology and Obstetrics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Arian Rezai
- Department of Gynecology and Obstetrics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Evelyn Klein
- Frauenklinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Marion Kiechle
- Department of Obstetrics and Gynecology, Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany
| |
Collapse
|
218
|
Paepke S, Allhorn S, Kiechle M. Primary and secondary prophylactic nipple-sparing subcutaneous mastectomy (NSSM): A retrospective single-center analysis. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.27_suppl.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
162 Background: Given a strict indication the NSSM is a oncologically safe surgical procedure and allows breast reconstructive interventions with a good cosmetic result. With regard to prophylactic mastectomy (PM) the (radical) ablatio mammae is so far regarded as the therapy of choice, since a maximal removement of the breast glandular tissue seems ensured. So far, it is unclear if NSSM is a oncologically safe treatment option also in the context of prophylactic surgery. The introduction of new materials for tissue extension in plastic-reconstructive interventions such as porcine acellular dermis (Strattice) or titanized polypropylene meshes (TiLoopBra) permits the reconstruction of the natural breast shape and size and thus the preservation of the body integrity also in prophylactic operations. Methods: This is a retrospective analysis of the PM performed at the Department of OB/GYN of the TU München (Munich, Germany) between 01/2005 and 12/2011 (76 cases). Primary PM were done in 13 cases due to positive family history (n=3), BRCA mutations (n=9) or at the request of the patient (n=1). 63 breast cancer patients were operated (secondary contralateral mastectomies) because of a positive familiy history (n=21), BRCA mutations (n=17) or high need for security (n=25). 19 mastectomies and 57 NSSMs were performed. With all NSSMs an instant reconstruction was done (17x expander, 25x implants, 1x TRAM, 14x DIEP), in 42 patients using a tissue extension (titanized poylpropylene meshes or acellular dermis). 9 patients with ablatio mammae received a breast reconstruction. Results: There was a continuous increase in prophylactic operations and NSSMs over the past five years. In four patients there was a coincidental pathological finding diagnosed in the healthy breast (2x DCIS, 1x Ca, 1x CLIS). In the group of primary prophylactic operated patients there were no (pre-)cancerous lesions found. In the secondary PM patients there were no recurrences, secondary cancers or metastases. Conclusions: In conclusion there was no difference between both surgical techniques with regard to oncologic safety. As far as breast reconstructive possibilities are concerned there are clear advantages in NSSM.
Collapse
Affiliation(s)
- Stefan Paepke
- Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany
| | - Svenja Allhorn
- Department of Gynecology and Obstetrics, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - Marion Kiechle
- Department of Obstetrics and Gynecology, Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany
| |
Collapse
|
219
|
Seiz L, Dorn J, Kotzsch M, Walch A, Grebenchtchikov NI, Gkazepis A, Schmalfeldt B, Kiechle M, Bayani J, Diamandis EP, Langer R, Sweep FCGJ, Schmitt M, Magdolen V. Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients. Biol Chem 2012; 393:391-401. [PMID: 22505521 DOI: 10.1515/hsz-2011-0264] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2011] [Accepted: 01/06/2012] [Indexed: 11/15/2022]
Abstract
Several members of the human kallikrein-related peptidase family, including KLK6, are up-regulated in ovarian cancer. High KLK6 mRNA or protein expression, measured by quantitative polymerase chain reaction and enzyme-linked immunoassay, respectively, was previously found to be associated with a shortened overall and progression-free survival (OS and PFS, respectively). In the present study, we aimed at analyzing KLK6 protein expression in ovarian cancer tissue by immunohistochemistry. Using a newly developed monospecific polyclonal antibody, KLK6 immunoexpression was initially evaluated in normal tissues. We observed strong staining in the brain and moderate staining in the kidney, liver, and ovary, whereas the pancreas and the skeletal muscle were unreactive, which is in line with previously published results. Next, both tumor cell- and stromal cell-associated KLK6 immunoexpression were analyzed in tumor tissue specimens of 118 ovarian cancer patients. In multivariate Cox regression analysis, only stromal cell-associated expression, besides the established clinical parameters FIGO stage and residual tumor mass, was found to be statistically significant for OS and PFS [high vs. low KLK6 expression; hazard ratio (HR), 1.92; p=0.017; HR, 1.80; p=0.042, respectively]. These results indicate that KLK6 expressed by stromal cells may considerably contribute to the aggressiveness of ovarian cancer.
Collapse
Affiliation(s)
- Lina Seiz
- Klinische Forschergruppe der Frauenklinik der Technischen Universität München, Klinikum rechts der Isar, Munich, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
220
|
Saucedo-Zeni N, Mewes S, Niestroj R, Gasiorowski L, Murawa D, Nowaczyk P, Tomasi T, Weber E, Dworacki G, Morgenthaler NG, Jansen H, Propping C, Sterzynska K, Dyszkiewicz W, Zabel M, Kiechle M, Reuning U, Schmitt M, Lücke K. A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol 2012; 41:1241-50. [PMID: 22825490 PMCID: PMC3583719 DOI: 10.3892/ijo.2012.1557] [Citation(s) in RCA: 135] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2012] [Accepted: 04/03/2012] [Indexed: 12/25/2022] Open
Abstract
The isolation of circulating tumor cells (CTCs) from the blood of patients afflicted with solid malignant tumors becomes increasingly important as it may serve as a 'liquid biopsy' with the potential of monitoring the course of the cancer disease and its response to cancer therapy, with subsequent molecular characterization. For this purpose, we functionalized a structured medical Seldinger guidewire (FSMW), normally used to obtain safe access to blood vessels and other organ cavities, with a chimeric monoclonal antibody directed to the cell surface expressed epithelial cell surface adhesion molecule (EpCAM). This medical device was optimized in vitro and its biocompatibility was tested according to the regulations for medical devices and found to be safe with no noteworthy side effects. Suitability, specificity and sensitivity of the FSMW to catch and enrich CTCs in vivo from circulating peripheral blood were tested in 24 breast cancer or non-small cell lung cancer (NSCLC) patients and in 29 healthy volunteers. For this, the FSMW was inserted through a standard venous cannula into the cubital veins of healthy volunteers or cancer patients for the duration of 30 min. After removal, CTCs were identified by immuno-cytochemical staining of EpCAM and/or cytokeratins and staining of their nuclei and counted. The FSMW successfully enriched EpCAM-positive CTCs from 22 of the 24 patients, with a median of 5.5 (0-50) CTCs in breast cancer (n=12) and 16 (2-515) CTCs in NSCLC (n=12). CTCs could be isolated across all tumor stages, including early stage cancer, in which distant metastases were not yet diagnosed, while no CTCs could be detected in healthy volunteers. In this observatory study, no adverse effects were noted. Evidently, the FSMW has the potential to become an important device to enrich CTCs in vivo for monitoring the course of the cancer disease and the efficacy of anticancer treatment.
Collapse
|
221
|
Seck K, Pfab S, Schmalzried H, Kiechle M, Schmalfeldt B. Welche Faktoren bestimmen die Prognose des Ovarialkarzinoms? Eine Analyse anhand eigener Daten von Primärfällen aus den Jahren 1997-2002. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1318579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
222
|
Seck K, Schuhmacher C, Schmalzried H, Kiechle M, Schmalfeldt B. Die optimale und standardisierte chirurgische Therapie und deren Dokumentation könnte die Prognose des Ovarialkarzinoms verbessern: Evaluierung eines standardisierten Staging-Algorythmus und einer reproduzierbaren Dokumentation. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1318580] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
223
|
Janni W, Harbeck N, Sommer HL, Rack BK, Augustin D, Simon W, Jueckstock JK, Wischnik A, Annecke K, Friese K, Kiechle M. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel versus FEC120 in the adjuvant treatment of node-positive breast cancer patients: Final survival analysis of the German ADEBAR phase III study. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.1081] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1081 Background: Based on meta-analytic evidence, taxane containing adjuvant chemotherapy has been established as standard treatment in breast cancer (BC). However, in the MA-21 study, adriamycin-cyclophosphamide, followed by paclitaxel was significantly inferior FEC120. We prospectively compared a sequential epirubicin-docetaxel chemotherapy regimen to FEC120. Methods: The ADEBAR study was a multicenter phase III trial (n=1502) to evaluate whether pts with > 3 axillary lymph node metastases BC benefit from a sequential anthracycline-docetaxel regimen (E90C–D: 4 cycles epirubicin [E] 90 mg/m2 plus cyclophosphamide [C] 600 mg/m2 q21d followed by 4 cycles docetaxel [D] 100mg/m2 q21d) compared to dose-intensive anthracycline-containing polychemotherapy (FE120C: 6 cycles E 60 mg/m² d 1+8, 5-FU 500mg/m² d 1+8 and C 75 mg/m² d 1-14, q4w). The observation time (median – 95%CI) was 49.5 (47.4 – 51.3) m. Results: Treatment was stopped prematurely in 3.7% of the pts in the E90C–D arm and in 8.0% in the FE120C arm due to toxicity (p=0.0009). Antibiotic treatment was given in 10.4% (E90C–D) vs. 19.7% (FE120C), G-CSF support in 39.2% vs 61.4 % and erythropoietin stimulation in 8.7% vs. 20.0%, respectively (p<0.0001). Haematological toxicity (leucopenia, neutropenic fever, thrombocytopenia, anemia) was significantly higher in the FEC-arm. At the time of the current analysis, 369 events of recurrence, were observed: 166 events in the FE120C group and 193 in the E90C–D group. The unadjusted hazard ratio (HR) was 0.877 (95 percent confidence interval, 0.722 to 1.065; p=0.3819, log-rank test). Overall survival in the two groups was not significantly different: (131 deaths with FEC vs. 134 with E90C–D (HR 0.996, 0.783-1.267, p=0.9691). Subgroup analyses, stratifying for tumor size, lymph node involvement, hormone receptor and HER2-neu status showed no significant difference between the two arms. Conclusions: Different toxicity profiles given, hematological toxicity in the FE120C group was more severe than in the E90C–D. In contrast to AC-P in earlier studies, EC-Doc provides a feasible and effective option to FEC120.
Collapse
Affiliation(s)
- Wolfgang Janni
- Universitätsklinikum Düsseldorf, Department of Gynecology and Obstetrics, Duesseldorf, Germany
| | - Nadia Harbeck
- Breast Center, Dept of OB&GYN, University of Munich, Munich, Germany
| | | | - Brigitte Kathrin Rack
- Department of Gynecology and Obstetrics, Klinikum der Ludwig-Maximilians-Universität, Munich, Germany
| | | | | | | | | | - Katja Annecke
- Department of Obstetrics and Gynecology, Technical University Munich, Munich, Germany
| | - Klaus Friese
- Department of Gynecology and Obstetrics, Klinikum der Ludwig-Maximilians-Universität, Munich, Germany
| | - Marion Kiechle
- Department of Obstetrics and Gynecology, Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany
| | | |
Collapse
|
224
|
Kasprowicz NS, Hepp PG, Andergassen U, Scholz C, Annecke K, Wischnik A, Simon W, Forstbauer H, Augustin D, Zwingers T, Harbeck N, Sommer HL, Friese K, Kiechle M, Janni W, Rack BK. Prognostic impact of weight change during chemotherapy. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.1072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1072 Background: Besides established prognostic factors such as tumor size or nodal status, individual host factors of the patient such as obesity, physical activity and diet seem to modulate the course of breast cancer (BC) as well. However, the specific impact of weight change during adjuvant chemotherapy remains unclear. The aim of this analysis was to evaluate the influence of weight change during chemotherapy on BC survival in a large, multi-center prospectively randomized trial. Methods: The ADEBAR trial compares two anthracycline based adjuvant chemotherapy regimen in patients (pts) with lymph node positive ( > 3 positive) early BC: 4 x epirubicin (E) 90 mg/m2 + cyclophosphamide (C) 600 mg/m2 q3w followed by 4 x docetaxel 100 mg/m2 q3w versus 6 x E 60 mg/m2 + 5-FU 500 mg/m2 d1+d8 and C 75 mg/m2 d1-14 q4w. Weight was measured before each cycle. The weight before the 1st and the 6th cycle was assessed. Significant weight change was defined as increase or decrease of > 5% of the initial weight. Overall survival (OS), disease free survival (DFS), and BC specific survival (BCSS) were assessed by Kaplan-Meier analysis. Results: In total, 1502 pts were included in the study. 1177 of them completed 6 cycles of chemotherapy. Out of the 350 pts (29.7%) who changed weight 142 pts (12.1%) lost and 208 pts (17.7 %) gained weight. There was a significant correlation between weight change and menopausal status (p<0.0001), indicating that more premenopausal pts gained and postmenopausal pts lost weight. All other tumor characteristics were similarly distributed across the groups. Pts with weight change > 5% showed a significantly worse outcome with respect to OS (p = 0.0028) and BCSS (p = 0.0258). A difference in DFS was not observed (p = 0.1917). The difference in OS was limited to pts who lost weight (p = 0.0008), whereas pts with weight gain have no significant different OS (p = 0.1246) in comparison to pts with constant weight. Conclusions: Our results suggest that weight loss during anthracycline-based treatment of early stage BC is associated with poorer OS. While weight normalization has shown beneficial effects in lifestyle intervention trials, patients should be advised not to lose weight during chemotherapy.
Collapse
Affiliation(s)
- Nikola S. Kasprowicz
- Department of Gynecology and Obstetrics, Heinrich Heine University, Duesseldorf, Germany
| | - Philip Gm Hepp
- Department of Gynecology and Obstetrics, Heinrich Heine University, Duesseldorf, Germany
| | - Ulrich Andergassen
- Department of Gynecology and Obstetrics, Ludwig-Maximilians-University, Munich, Germany
| | - Christoph Scholz
- Department of Gynecology and Obstetrics, Heinrich Heine University, Duesseldorf, Germany
| | - Katja Annecke
- Department of Obstetrics and Gynecology, Technical University Munich, Munich, Germany
| | | | | | | | | | | | - Nadia Harbeck
- Breast Center, Department of Obstetrics and Gynecology, Ludwig-Maximilians-University, Munich, Germany
| | - Harald Leo Sommer
- Department of Gynecology, Cancer Center of the Ludwig-Maximilians-University, Munich, Germany
| | - Klaus Friese
- Department of Gynecology and Obstetrics, Ludwig-Maximilians-University, Munich, Germany
| | - Marion Kiechle
- Department of Obstetrics and Gynecology, Technical University Munich, Munich, Germany
| | - Wolfgang Janni
- Department of Gynecology and Obstetrics, Heinrich Heine University, Duesseldorf, Germany
| | - Brigitte Kathrin Rack
- Department of Gynecology and Obstetrics, Ludwig-Maximilians-University, Munich, Germany
| |
Collapse
|
225
|
Jackisch C, Lück HJ, Untch M, Bischoff J, Müller V, Schmidt M, Thill M, Kiechle M. Weekly nab-Paclitaxel in Metastatic Breast Cancer - Summary and Results of an Expert Panel Discussion. ACTA ACUST UNITED AC 2012; 7:137-143. [PMID: 22740801 DOI: 10.1159/000338273] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Taxanes are regarded as the most effective single agents in the treatment of metastatic breast cancer (MBC). For conventional taxanes, crucial toxicities and impairments in clinical efficacy are related to solvents necessary because of the agents' hydrophobicity. The mandatory premedication with corticosteroids causes additional side effects. Nab-paclitaxel is a solvent-free colloidal suspension of paclitaxel and human serum albumin that exploits the physiological transport properties of albumin. It is registered as monotherapy with a recommended dose of 260 mg/m(2) every 3 weeks for the treatment of patients with MBC, who have failed a first-line treatment of metastatic disease and for whom a standard anthracycline treatment is not indicated. Clinical evidence is available for the registered 3-weekly administration and for alternative weekly schedules in first and further lines of therapy of patients with MBC. During an advisory board meeting, a group of 8 German breast cancer experts reviewed the clinical data of nab-paclitaxel in MBC and discussed how nab-paclitaxel could be used in clinical practice on the basis of the current data.
Collapse
|
226
|
Garcia-Etienne CA, Tomatis M, Heil J, Friedrichs K, Kreienberg R, Denk A, Kiechle M, Lorenz-Salehi F, Kimmig R, Emons G, Danaei M, Heyl V, Heindrichs U, Rageth CJ, Janni W, Marotti L, del Turco MR, Ponti A. Mastectomy trends for early-stage breast cancer: a report from the EUSOMA multi-institutional European database. Eur J Cancer 2012; 48:1947-56. [PMID: 22483323 DOI: 10.1016/j.ejca.2012.03.008] [Citation(s) in RCA: 79] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2012] [Revised: 02/23/2012] [Accepted: 03/03/2012] [Indexed: 11/17/2022]
Abstract
INTRODUCTION Recent single-institution reports have shown increased mastectomy rates during the last decade. Further studies aiming to determine if these reports could be reflecting a national trend in the United States of America (US) have shown conflicting results. We report these trends from a multi-institutional European database. PATIENTS AND METHODS Our source of data was the eusomaDB, a central data warehouse of prospectively collected information of the European Society of Breast Cancer Specialists (EUSOMA). We identified patients with newly diagnosed unilateral early-stage breast cancer (stages 0, I or II) to examine rates and trends in surgical treatment. RESULTS A total of 15,369 early-stage breast cancer cases underwent surgery in 13 Breast Units from 2003 to 2010. Breast conservation was successful in 11,263 cases (73.3%). Adjusted trend by year showed a statistically significant decrease in mastectomy rates from 2005 to 2010 (p = 0.003) with a progressive reduction of 4.24% per year. A multivariate model showed a statistically significant association of the following factors with mastectomy: age < 40 or ≥ 70 years, pTis, pT1mi, positive axillary nodes, lobular histology, tumour grade II and III, negative progesterone receptors and multiple lesions. CONCLUSION Our study demonstrates that a high proportion of patients with newly diagnosed unilateral early-stage breast cancer from the eusomaDB underwent breast-conserving surgery. It also shows a significant trend of decreasing mastectomy rates from 2005 to 2010. Moreover, our study suggests mastectomy rates in the population from the eusomaDB are lower than those reported in the US.
Collapse
Affiliation(s)
- Carlos A Garcia-Etienne
- Breast Unit, Humanitas Cancer Center, Milan, Rozzano, Italy; EUSOMA Data Centre, Turin, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
227
|
Seifert-Klauss V, Fillenberg S, Schneider H, Luppa P, Mueller D, Kiechle M. Bone loss in premenopausal, perimenopausal and postmenopausal women: results of a prospective observational study over 9 years. Climacteric 2012; 15:433-40. [PMID: 22443333 DOI: 10.3109/13697137.2012.658110] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- V Seifert-Klauss
- Frauenklinik und Poliklinik der TU München, Klinikum rechts der Isar, München, Germany
| | | | | | | | | | | |
Collapse
|
228
|
Kiechle M, Klein E, Paepke D, Bronger H, Ettl J, Paepke S. 448 Use of Acellular Dermis (Strattice TM) in Problematic Cases of Breast Reconstructive Surgery. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70513-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
229
|
Schmidmayr M, Wimmer T, Fillenberg S, Baumgartner L, Kiechle M, Seifert-Klauss V. 104 FSH AND PERIMENOPAUSAL BONE DENSITY. Maturitas 2012. [DOI: 10.1016/s0378-5122(12)70215-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
230
|
Dittmer S, Paepke S, Klein E, Ohlinger R, Kiechle M. 614 First Experiences with the Implementation of a Two Component Polypropylen-vicryl Mesh (SERAGYN® BR) as Tissue-supporting Extraneous Material in Plastic Reconstructive Surgery. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70679-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
231
|
Paepke S, Dittmer S, Rezai A, Klein E, Kiechle M. 575 Subpectoral Implants in Oncoplastic-reconstructive Breast Surgery–Habit or Necessity? Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70640-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
232
|
Fillenberg S, Johanna L, Loreen R, Schmidmayr M, Artmann A, Kiechle M, Seifert-Klauss V. 13 VITAMIN D AND BREAST DENSITY IN PRE- AND POSTMENOPAUSAL WOMEN. Maturitas 2012. [DOI: 10.1016/s0378-5122(12)70124-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
233
|
Klein E, Kiechle M, Ettl J, Paepke D, Paepke S. 613 Analysis of Immediate Breast Reconstruction with the Use of Titanized Polypropylene Mesh (TiLOOP® Bra). Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70678-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
234
|
Bronger H, Kraeft S, Schwarz-Boeger U, Cerny C, Stöckel A, Avril S, Kiechle M, Schmitt M. Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer. Breast Cancer Res 2012; 14:R30. [PMID: 22333315 PMCID: PMC3496148 DOI: 10.1186/bcr3115] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2012] [Revised: 01/13/2012] [Accepted: 02/14/2012] [Indexed: 12/14/2022] Open
Abstract
Introduction In murine breast cancer models, the two interferon-gamma (IFN-γ) inducible chemokines and CXC-chemokine receptor 3 (CXCR3) receptor ligands, monokine induced by γ-interferon (CXCL9) and interferon-γ-inducible protein-10 (CXCL10) impair tumor growth and metastasis formation through recruitment of natural killer (NK) cells and tumor-suppressive T lymphocytes. In human breast cancer, CXCL9 mRNA overexpression correlates with the number of tumor infiltrating lymphocytes and predicts response to different chemotherapeutic regimens. Raising the intratumoral CXCR3 ligand concentration is therefore a possible way to enhance immune intervention in breast cancer. Little is known, however, about expression levels and regulation of these chemokines in human breast cancer. Since the inhibition of cyclooxygenases (COX) has been shown to reduce tumor growth and incidence of metastases in a lymphocytic and IFN-γ dependent manner, we argued that COX isoenzymes are a pharmacologic target to increase intratumoral CXCR3 ligand concentration in human breast cancer. Methods CXCL9 was visualized in breast cancer specimens by immunohistochemistry, expression levels of CXCL9 and cyclooxygenases were determined by ELISA and western blotting, respectively. For regulation studies, Michigan Cancer Foundation-7 (MCF-7) and M.D. Anderson - Metastatic Breast 231 (MDA-MB 231) breast cancer cells were stimulated with IFN-γ with or without prostaglandin E2 (PGE2) or COX inhibitors (indomethacin, acetylsalicylic acid (ASA), celecoxib). CXCR3 ligand release from cells was measured by ELISA. Results Within the tumor microenvironment, cancer cells are the major source of CXCL9. PGE2 impairs IFN-γ mediated CXCL9 and CXCL10 release from MCF-7 and MDA-MB 231 cells, and inhibition of endogenous cyclooxygenases by indomethacin or ASA correspondingly increases this secretion. Otherwise, high concentrations of the Cyclooxygenase-2 (COX-2) specific antagonist celecoxib have opposite effects and impair CXCL9 and CXCL10 release. In human breast cancer tissue specimens there is an inverse correlation between COX-2 overexpression and CXCL9 concentration, suggesting that the observed in vitro effects are of importance in vivo as well. Conclusions Suppressing endogenous PGE2 synthesis by cyclooxygenase inhibition increases CXCL9 and CXCL10 release from breast cancer cells and is therefore a pharmacologic candidate to enhance intratumoral immune infiltration. Yet, to this end the unselective COX inhibitors ASA and indomethacin seem preferable to celecoxib that at higher concentrations reduces CXCR3 ligand release most probably due to COX independent mechanisms.
Collapse
Affiliation(s)
- Holger Bronger
- Department of Gynecology and Obstetrics, Technische Universität München, Ismaninger Str, 22, 81675 Munich, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
235
|
Hoenicka M, Jacobs V, Niemeyer M, Bronger H, Schneider K, Kiechle M, Huber G, Seelbach-Göbel B, Burkhart J, Hammer J, Liepsch D, Schmid C, Birnbaum D. Neue Verwendungsmöglichkeiten von Nachgeburtsgewebe für die Regenerative Medizin. Z Geburtshilfe Neonatol 2012; 216:27-33. [DOI: 10.1055/s-0031-1298029] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- M. Hoenicka
- Klinik für Herz-, Thorax- und herznahe Gefäßchirurgie, Klinikum der Universität Regensburg
- Klinik für Herz-, Thorax- und Gefäßchirurgie, Universitätsklinikum Ulm
| | - V. Jacobs
- Frauenklinik, Technische Universität München
- Frauenklinik, Paracelsus Medizinische Universität, Salzburg, Austria
| | - M. Niemeyer
- Frauenklinik, Technische Universität München
| | - H. Bronger
- Frauenklinik, Technische Universität München
| | | | - M. Kiechle
- Frauenklinik, Technische Universität München
| | - G. Huber
- Abteilung für Frauenheilkunde und Geburtshilfe, Klinik St. Hedwig, Krankenhaus Barmherzige Brüder, Regensburg
| | - B. Seelbach-Göbel
- Abteilung für Frauenheilkunde und Geburtshilfe, Klinik St. Hedwig, Krankenhaus Barmherzige Brüder, Regensburg
| | - J. Burkhart
- Blutspendedienst des Bayerischen Roten Kreuzes, München
| | - J. Hammer
- FB Maschinenbau, Hochschule Regensburg
| | - D. Liepsch
- FB05 Versorgungstechnik, Hochschule München
| | - C. Schmid
- Klinik für Herz-, Thorax- und herznahe Gefäßchirurgie, Klinikum der Universität Regensburg
| | - D. Birnbaum
- Klinik für Herz-, Thorax- und herznahe Gefäßchirurgie, Klinikum der Universität Regensburg
| |
Collapse
|
236
|
Kotzsch M, Dorn J, Doetzer K, Schmalfeldt B, Krol J, Baretton G, Kiechle M, Schmitt M, Magdolen V. mRNA expression levels of the biological factors uPAR, uPAR-del4/5, and rab31, displaying prognostic value in breast cancer, are not clinically relevant in advanced ovarian cancer. Biol Chem 2012; 392:1047-51. [PMID: 21848504 DOI: 10.1515/bc.2011.166] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
High tumor tissue mRNA expression of the tumor biological factors uPAR, uPAR-del4/5, or rab31 is associated with shorter distant metastasis-free and overall survival in breast cancer patients. To evaluate whether these factors are also clinically relevant in ovarian cancer, we quantified the respective mRNA levels in primary tumor tissue of advanced ovarian cancer patients (n=103) and evaluated their association with clinicopathological parameters and patients' prognosis. mRNA expression levels of all three markers did not show any significant association with overall or progression-free survival, demonstrating that these factors have no prognostic value in advanced ovarian cancer.
Collapse
Affiliation(s)
- Matthias Kotzsch
- Institut für Pathologie, Technische Universität Dresden, D-01307 Dresden, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
237
|
Wiedemann F, Büssing A, Halle M, Kiechle M, Kohls N, Ostermann T, Sattler D, Ettl J. OT3-02-02: Yoga Compared to Exercise as a Therapeutic Intervention during (Neo)adjuvant Chemotherapy in Women with Stage I-III Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-ot3-02-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Psychological and physical distress is high in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy. The ***patients'ability to cope with this distress has an impact on treatment variables, i.e. deliverable chemotherapy dose, tolerabilty of side effects, and finaly treatment completion rate. Exercise intervention studies have shown physiological and psychological benefits when undertaken during cancer treatment. There is also evidence that mind/body interventions such as yoga are useful to manage treatment-related symptoms and anxiety in breast cancer patients. Considering the specific theoretical background of mind/body interventions this ongoing trial aims to elucidate the different effects of yoga and conventional exercise on physical and psychological factors in breast cancer patients undergoing neoadjuvant or adjuvant chemotherapy. Trial design: Longitudinal data collection within an open, prospective, randomized trial using standardized questionnaires about inner correspondence and peacefulness with practices (ICPH), health-related quality of life (EORTC QLC C-30), fatigue (Cancer Fatigue Scale, CFS-D), mindfulness (Freiburg Mindfulness Inventory, FMI), spiritual/religious attitudes and disease coping (SpREUK), and life satisfaction (Brief Multidimensional Life Satisfaction Scale, BMLSS). Patients with newly diagnosed stage I-III breast cancer undergoing neoadjuvant or adjuvant chemotherapy are randomly assigned to receive yoga or conventional exercise on a 1:1 ratio. The yoga intervention consists of a weekly 60-minute Iyengar-Yoga group-session together with individual home-based, selfcontained 20-minute sessions twice a week. The conventional exercise intervention consists of a weekly 60-minute physiotherapy exercise session together with individual home-based, selfcontained 20-minute sessions twice a week. Data assessments via questionnaires are done at baseline, right after the 12-week intervention period and 2 months after the end of intervention. Statistical analysis includes analysis of variance with all collected parameters and analysis of correlation between ICPH and above parameters. For statistical power 1-β=0.8 and twosided probability of error a=0.05 the target accrual is 120 patients. Patient accrual within two breast care units started in April 2011 with 12 patients being on study to date (2011, June 21). Planned period of accrual is 20 months.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT3-02-02.
Collapse
Affiliation(s)
- F Wiedemann
- 1Technische Universität München, Munich, Germany; Universität Witten/Herdecke, Herdecke, Germany; Praxis Gynäkologie Arabella, Munich, Germany; Ludwig-Maximilians-Universität München, Bad Tölz, Germany
| | - A Büssing
- 1Technische Universität München, Munich, Germany; Universität Witten/Herdecke, Herdecke, Germany; Praxis Gynäkologie Arabella, Munich, Germany; Ludwig-Maximilians-Universität München, Bad Tölz, Germany
| | - M Halle
- 1Technische Universität München, Munich, Germany; Universität Witten/Herdecke, Herdecke, Germany; Praxis Gynäkologie Arabella, Munich, Germany; Ludwig-Maximilians-Universität München, Bad Tölz, Germany
| | - M Kiechle
- 1Technische Universität München, Munich, Germany; Universität Witten/Herdecke, Herdecke, Germany; Praxis Gynäkologie Arabella, Munich, Germany; Ludwig-Maximilians-Universität München, Bad Tölz, Germany
| | - N Kohls
- 1Technische Universität München, Munich, Germany; Universität Witten/Herdecke, Herdecke, Germany; Praxis Gynäkologie Arabella, Munich, Germany; Ludwig-Maximilians-Universität München, Bad Tölz, Germany
| | - T Ostermann
- 1Technische Universität München, Munich, Germany; Universität Witten/Herdecke, Herdecke, Germany; Praxis Gynäkologie Arabella, Munich, Germany; Ludwig-Maximilians-Universität München, Bad Tölz, Germany
| | - D Sattler
- 1Technische Universität München, Munich, Germany; Universität Witten/Herdecke, Herdecke, Germany; Praxis Gynäkologie Arabella, Munich, Germany; Ludwig-Maximilians-Universität München, Bad Tölz, Germany
| | - J Ettl
- 1Technische Universität München, Munich, Germany; Universität Witten/Herdecke, Herdecke, Germany; Praxis Gynäkologie Arabella, Munich, Germany; Ludwig-Maximilians-Universität München, Bad Tölz, Germany
| |
Collapse
|
238
|
Jacobs VR, Mayer SC, Paessens BJ, Bernard R, Harbeck N, Kiechle M, Ihbe-Heffinger A. Comparison of actual hospital costs versus DRG revenues for in-patient treatment of febrile neutropenia during adjuvant anthracycline plus/minus taxane-based chemotherapy for primary breast cancer. Onkologie 2011; 34:614-8. [PMID: 22104158 DOI: 10.1159/000334063] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND In flat-rate reimbursement systems, the hospital's own costs should not exceed its revenues. In a cohort of primary breast cancer (pBC) patients, costs and reimbursement for febrile neutropenia (FN) were compared to verify cost coverage. METHODS A prospective, observational study in pBC patients receiving adjuvant anthracycline ± taxane-based chemotherapy calculated the costs per in-patient FN episode. The correlating revenues were retrospectively analyzed from diagnosis-related group (DRG) invoices. The actual costs of the therapies were compared to the individual DRG revenues, and the results are presented from the provider's perspective. RESULTS In 50 patients, n = 11 patients were treated for FN as in-patients. The hospital's overall treatment costs were € 18,288, on average (Ø) € 1663 per case (range € 1139-2344); the overall DRG revenues were € 23,593, Ø € 2145 per case (range € 1266-2660). In n = 8 cases, the DRGs were cost covering, and in n = 3 cases, a loss was observed, but overall resulting in a gain of Ø € 482 per case and thus being cost covering for the provider. Inadequate DRG coding (n = 4/11; 36.4%) resulted in a preventable loss of Ø € 1069/case. CONCLUSIONS The costs of FN treatment vary substantially and DRG reimbursements do not necessarily reflect the provider's costs. Surprisingly, the in-patient treatment of FN here is overall more than cost covering if adequately coded. The main reasons are asymmetrical costs for this FN low-risk pBC group. These results emphasize the importance of correct medical coding to avoid potential losses.
Collapse
Affiliation(s)
- Volker R Jacobs
- Frauenklinik, OB/GYN, Klinikum rechts der Isar, Technische Universität München, Germany.
| | | | | | | | | | | | | |
Collapse
|
239
|
Bronger H, Kraeft S, Stöckel A, Welk A, Kiechle M, Schmitt M, Schwarz-Boeger URM. Effect of cyclooxygenase inhibition on CXCR3 ligand secretion in breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.45] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
45 Background: In murine cancer models, the two IFN-γ inducible chemokines CXCL9 and CXCL10, those bind to the common receptor CXCR3, recruit NK cells and tumor-suppressive lymphocytes into the tumor site and impair tumor growth and metastatic spread. In human breast cancer (BC), we and others have shown that high levels of CXCL9 mRNA correlate with favorable prognosis and the number of infiltrating lymphocytes. Raising the intratumoral level of CXCR3 ligands might therefore be a feasible way to enhance the infiltration by tumor-suppressive immune cells and to improve immune intervention in breast cancer. Inhibition of cyclooxygenases (COX) has been shown to inhibit tumor growth and metastases formation in a lymphocytic and IFN-γ dependent manner. We therefore tested whether COX inhibition induces CXCR3 ligand secretion from breast cancer cells. Methods: Human MCF-7 and MDA-MB 231 BC cells were stimulated with IFN-γ with or without prostaglandin E2 (PGE2) or COX inhibitors (indomethacin, aspirin, celecoxib). CXCL9 and CXCL10 release was measured by ELISA. COX-1 and COX-2 expression was measured in 45 BC samples and correlated with intratumoral CXCR3 ligand concentration. Results: Prostaglandin E2 inhibits CXCL10 and CXCL9 release from breast cancer cells. Aspirin and indomethacin enhance the INF-γ mediated secretion of these CXCR3 ligands by inhibition of endogenous cyclooxygenases. Celecoxib has this effect only at low concentrations, at higher concentrations is shows PGE2 agonistic effects. In human breast cancer samples, COX-2 overexpression inversely correlates with CXCR3 ligand concentration, which shows that the mechanism of PGE2 induced CXCL9/CXCL10 suppression might also be relevant in vivo. Conclusions: Suppressing endogenous PGE2 by cyclooxygenase inhibition increases CXCL9 and CXCL10 release from breast cancer cells and is therefore a feasible way to enhance the infiltration of breast tumors by tumor-suppressive lymphocytes. However, our results show that unselective COX inhibitors might be more suitable than the COX-2 specific celecoxib. Clinical trials are now warranted to clarify the mechanisms and therapeutic efficacy of COX inhibition in breast cancer.
Collapse
Affiliation(s)
- H. Bronger
- Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany; Department of Obstetrics and Gynecology, Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany
| | - S. Kraeft
- Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany; Department of Obstetrics and Gynecology, Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany
| | - A. Stöckel
- Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany; Department of Obstetrics and Gynecology, Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany
| | - A. Welk
- Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany; Department of Obstetrics and Gynecology, Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany
| | - M. Kiechle
- Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany; Department of Obstetrics and Gynecology, Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany
| | - M. Schmitt
- Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany; Department of Obstetrics and Gynecology, Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany
| | - U. R. M. Schwarz-Boeger
- Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany; Department of Obstetrics and Gynecology, Klinikum r.d. Isar Frauenklinik, Technische Universitaet Muenchen, Munich, Germany
| |
Collapse
|
240
|
Ari F, Napieralski R, Ulukaya E, Dere E, Colling C, Honert K, Krüger A, Kiechle M, Schmitt M. Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine. Cell Biochem Funct 2011; 29:651-9. [DOI: 10.1002/cbf.1801] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2011] [Revised: 06/07/2011] [Accepted: 08/01/2011] [Indexed: 01/13/2023]
Affiliation(s)
- Ferda Ari
- Department of Biology; Faculty of Science and Art; Uludag University; Bursa; Turkey
| | - Rudolf Napieralski
- Department of Obstetrics and Gynecology; Technische Universitaet Muenchen; Klinikum rechts der Isar; Munich; Germany
| | - Engin Ulukaya
- Department of Medical Biochemistry; Medical School of Uludag University; Bursa; Turkey
| | - Egemen Dere
- Department of Biology; Faculty of Science and Art; Uludag University; Bursa; Turkey
| | - Christoph Colling
- Department of Obstetrics and Gynecology; Technische Universitaet Muenchen; Klinikum rechts der Isar; Munich; Germany
| | - Katja Honert
- Institute for Experimental Oncology and Therapy Research; Technische Universitaet Muenchen; Klinikum rechts der Isar; Munich; Germany
| | - Achim Krüger
- Institute for Experimental Oncology and Therapy Research; Technische Universitaet Muenchen; Klinikum rechts der Isar; Munich; Germany
| | - Marion Kiechle
- Department of Obstetrics and Gynecology; Technische Universitaet Muenchen; Klinikum rechts der Isar; Munich; Germany
| | - Manfred Schmitt
- Department of Obstetrics and Gynecology; Technische Universitaet Muenchen; Klinikum rechts der Isar; Munich; Germany
| |
Collapse
|
241
|
Rhiem K, Engel C, Graeser M, Kiechle M, Ditsch N, Mundhenke C, Kreienberg R, Tio J, Golatta M, Hönig A, Gadzicki D, Speiser D, Kast K, Briest S, Meindl A, Schmutzler R. Kontralaterales Mammakarzinom-Risiko bei BRCA1/2-negativen Patientinnen mit familiärer Hochrisikosituation. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1286442] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
242
|
Bronger H, Kraeft S, Schmitt M, Kiechle M. Regulation des CXCR3-Chemokin-Systems durch Hemmung der Cyclooxygenase – eine Möglichkeit zur Verbesserung der Immunintervention beim Mammakarzinom. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1286448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
243
|
Paepke S, Kiechle M. Medikamentöse und operative Prävention des Mammakarzinoms. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1286447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
244
|
Jansen H, Nedorezova E, Hellmann D, Kiechle M, Schmitt M. Stellenwert von GPR30 als Biomarker beim triple-negativen Mammakarzinom. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1286449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
245
|
Baumgärtner AK, Häusler A, Seifert-Klauss V, Schuster T, Schwarz-Boeger U, Kiechle M. Breast cancer after hormone replacement therapy--does prognosis differ in perimenopausal and postmenopausal women? Breast 2011; 20:448-54. [PMID: 21652211 DOI: 10.1016/j.breast.2011.04.010] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2010] [Revised: 01/09/2011] [Accepted: 04/24/2011] [Indexed: 11/18/2022] Open
Abstract
Hormone replacement therapy (HRT) has been associated with higher incidence of breast cancer in postmenopausal women, but it is unclear if breast cancers developing after HRT use have different prognosis. 1053 women with hormone receptor positive non-metastasized breast cancer were analyzed in a retrospective trial, stratifying by HRT use before diagnosis. Postmenopausal HRT users had significantly more early tumor stages (p<0.001). HRT in postmenopausal patients was associated with longer time to progression (TTP) (HR 0.81, 95%CI 0.55-1.19, p=0.28) and overall survival (OS) (HR 0.68, 95%CI 0.45-1.02, p=0.059). Perimenopausal HRT users showed shorter TTP and OS (HR 1.99, 95%CI 0.57-6.91, p=0.28 and HR 4.59, 95%CI 0.91-23.25, p=0.06 respectively). Higher BMI was significantly associated with poorer prognosis in perimenopausal women only (TTP: HR=1.16; OS: HR=1.31). In this retrospective analysis postmenopausal HRT users seemed to have a better breast cancer prognosis. For perimenopausal HRT users however, a trend towards worse prognosis was found.
Collapse
Affiliation(s)
- A K Baumgärtner
- Frauenklinik rechts der Isar der Technischen Universität München, Ismaninger Str. 22, 81675 München, Germany.
| | | | | | | | | | | |
Collapse
|
246
|
Untch M, Gerber B, Möbus V, Schneeweiss A, Thomssen C, Minckwitz GV, Beckmann M, Blohmer JU, Costa SD, Diedrich K, Diel I, Eiermann W, Friese K, Harbeck N, Hilfrich J, Jackisch C, Janni W, Jänicke F, Jonat W, Kaufmann M, Kiechle M, Köhler U, Kreienberg R, Maass N, Marschner N, Nitz U, Scharl A, Wallwiener D. St.-Gallen-Konferenz 2011 zum primären Mammakarzinom. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0030-1271133] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
247
|
Bronger H, Schwarz-Boeger URM, Kraeft S, Stöckel A, Welk A, Kiechle M, Schmitt M. The effects of cyclooxygenase inhibition on CXCR3 ligand secretion in breast cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e21158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
248
|
Janni JW, Hepp PGM, Andergassen U, Harbeck N, Rack BK, Neugebauer JK, Annecke K, Wischnik A, Simon W, Rezai M, Fehm TN, Schneeweiss A, Fasching PA, Gerber B, Zwingers T, Sommer HL, Friese K, Kiechle M. Final multivariate analysis of obesity and survival in patients with node-positive primary breast cancer: The ADEBAR trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
249
|
Rhiem K, Engel C, Graeser M, Janni W, Kiechle M, Ditsch N, Mundhenke C, Kreienberg R, Tio J, Golatta M, Honig A, Gadzicki D, Speiser D, Kast K, Briest S, Meindl A, Schmutzler R. Contralateral breast cancer risk in patients with familial breast cancer who tested negative for BRCA1 and BRCA2. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
250
|
Platzer B, Ehle A, Wimmer T, Kiechle M, Seifert-Klauss V. Die Perimenopausale Knochendichte und Ovulation (PEKNO)- Studie: Symptome und Beschwerden in der Perimenopause. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1278593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|